The ELISpot and FluoroSpot assay market made USD 289.5 million revenue in 2023, and it will power at a compound annual growth rate of 7.9% by the end of this decade, to touch a total value of USD 490.8 million by 2030.
 |
| To learn more about this report: https://bit.ly/47ili1C |
Some factors which are powering the industry are the increasing occurrence of chronic and communicable ailments at the global level, particularly HIV, and the growing elderly populace. ELISpot and FluoroSpot are diagnosis assays made for numerous diseases, for example infectious disease, cancer, and, autoimmune ailments.
Assay kits will have the largest share in the years to come as a result of the increasing incidence of infectious and chronic diseases, accompanied by the progression in assay kits. The ELISpot assay is also put to use for checking the efficiency of vaccines on immune mediators, for example, interferons, pro-inflammatory mediators, and interleukins.
North America leads the industry with a share, of 55%, in 2023. As per the U.S. Census Bureau, about 56 million adults aged 65 or more are in the U.S. and will be around 16.9% of the national populace.
Further, there will be over 73 million older adults by the end of 2030, meaning over 1 in 5 people will be older. The total count of adults aged 65 and more will increase to 85.7 million by 2050 and account for around 22% of the overall populace of the nation.
It is because of the growing elderly population all over the world, the demand for ELISpot and FluoroSpot assays is on the rise. This trend will continue to grow in the years to come as well.
